In the adjuvant setting, the OlympiA trial demonstrated improvements in overall survival (OS) after curative intent therapy in patients with germline pathogenic variants (gPVs) in BRCA1/2 in high-risk, early breast cancer (10,11). This evidence concerns the gene BRCA1 and breast carcinoma.